KINTOR PHARMA-B (09939) signs strategic cooperation agreement with FUNO Pharmaceuticals to promote the market transformation and expansion of efficacy cosmetics ingredient KT-939.

KINTOR PHARMA-B (09939) announced on March 12, 2026, that its fully-owned subsidiary, Suzhou Kaituo Pharmaceutical Co., Ltd. (Suzhou Kaituo), has entered into a strategic cooperation agreement with Zhejiang Funuo Pharmaceutical Co., Ltd. (Funuo Medical) regarding the joint development of the whitening and spot-removing cosmetic product containing the company's innovative ingredient KT-939, as an auxiliary method to alleviate and improve skin pigmentation. According to the cooperation agreement, Suzhou Kaituo will provide KT-939 raw materials to Funuo Medical and authorize it to develop, produce, and sell whitening and spot-removing products with KT-939 as the core active ingredient in mainland China, as an adjuvant to its core product Funlim cream for treating melasma. The two parties will collaborate deeply on technical improvements and end-product development, accelerating the research and development, registration, and production of specialty cosmetics containing KT-939 raw materials, with Funuo Medical responsible for later sales. The company plans to use the cash flow generated from the KT-939 functional cosmetic raw materials business to provide funding support for the development and commercialization (listing business) of its core products KX-826 and GT20029, as well as other pipeline products. At the same time, the company will continue to adhere to its established policy on listed business. The cooperation agreement with Funuo Medical aims to establish a long-term stable strategic partnership, fully leveraging the complementary advantages of both parties in innovative raw material development and skin topical product development, and promoting the market transformation and expansion of the functional cosmetic raw material KT-939. Through this cooperation, Suzhou Kaituo will further accelerate the commercialization process of KT-939, expand its market coverage and influence, realize the transformation of technological advantages into market value, and provide auxiliary support for frontline treatment for a large number of patients with melasma. The cash flow generated from the sale of KT-939 will provide funding support for the development and commercialization of the company's core products KX-826 and GT20029.